Helicobacter pylori and idiopathic central serous chorioretinopathy

Swiss Medical Weekly

Volumn 134, Issue 27-28, 2004, Pages 395-398

  Giusti, Cristiano ^a,c   Mauget Faÿsse, Martine ^b  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b Centre Ophtalmologique Rabelais   (France)

^c NONE   (Italy)

Author keywords

Helicobacter pylori; Idiopathic central serous chorioretinopathy; Macula; Retina

Indexed keywords

CHORIORETINOPATHY; DISEASE ASSOCIATION; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; IDIOPATHIC CENTRAL SEROUS CHORIORETINOPATHY; PATHOPHYSIOLOGY; RETINA MACULA LUTEA; RETINA PIGMENT EPITHELIOPATHY; SHORT SURVEY; VISUAL IMPAIRMENT;

EID: 4043123232     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (38)

1. Albert DM, Jakobiec FA. Principles and practice of ophthalmology. Philadelphia: Saunders, 1994.
2. Iida T, Yannuzzi LA, Spaide RF, et al. Cystoid macular degeneration in chronic central serous chorioretinopathy. Retina 2003;23:1-7
3. Teschner S, Noack J, Birngruber R, Schmidt-Erfurth U. Characterization of leakage activity in exudative chorioretinal disease with three-dimensional confocal angiography. Ophthalmology 2003;110:687-97.
4. Spaide RE. Deposition of yellow submacular material in central serous chorioretinopathy resembling adult-onset foveomacular vitelliform dystrophy. Retina 2004;24:301-304.
5. Yannuzzi LA, Slakter JS, Gross NE, et al. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina 2003;23:288-98.
6. Cardillo Piccolino F, Eandi CM, Ventre L, et al. Photodynamic therapy for chronic central serous chorioretinopathy. Retina 2003;23:752-63.
7. Canakis C, Conway MD, Livir-Rallatos C, et al. Ocular photodynamic therapy in choroidal neovascularization complicating idiopathic central serous chorioretinopathy. Ophthalmic Surg Lasers Imaging 2004;35:168-71.
8. Ergun E, Tittl M, Stur M. Photodynamic therapy with verteporfin in subfoveal choroidal neovascularization secondary to central serous chorioretinopathy. Arch Ophthalmol 2004; 122:37-41.
9. Ricci F, Missiroli F, Cerulli L. Indocyanine green dye-enhanced micropulsed diode laser: a novel approach to subthreshold RPE treatment in a case of central serous chorioretinopathy. Eur J Ophthalmol 2004;14:74-82.
10. Haimovici R, Koh S, Gagnon DR, et al. Risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology 2004;111:244-9.
11. Allibhai ZA, Gale JS, Sheidow TS. Central serous chorioretinopathy in a patient taking sildenafil citrate. Ophthalmic Surg Lasers Imaging 2004;35:165-7.
12. Carvalho-Recchia CA, Yannuzzi LA, Negrao S, et al. Corticosteroids and central serous chorioretinopathy. Ophthalmology 2002;109:1834-7
13. Koyama M, Mizota A, Igarashi Y, Adachi-Usami E. Seventeen cases of central serous chorioretinopathy associated with systemic corticosteroid therapy. Ophthalmologica 2004;218:107-10.
14. Michael JC, Pak J, Pulido J, de Venecia G. Central serous chorioretinopathy associated with administration of sympathomimetic agents. Am J Ophthalmol 2003;136:182-5.
15. Costen MT, Parkin BT, Davison CR, et al. Central serous chorioretinopathy and antiphospholipid antibodies - results of a pilot study. Eye 2004 (in press).
16. Dorenboim Y, Rehany U, Rumelt S. Central serous chorioretinopathy associated with retinitis pigmentosa. Graefes Arch Clin Exp Ophthalmol 2004;242:346-9.
17. Nucci C, Corsi A, Mancino R, Macri G. Central serous chorioretinopathy in patients with psoriasis. Acta Ophthalmol Scand 2004;82:105-7.
18. Haimovici R, Rumelt S, Melby J. Endocrine abnormalities in patients with central serous chorioretinopathy. Ophthalmology 2003;110:698-703.
19. Katsimpris JM, Vandoros M, Petropoulos IK, et al. Central serous chorioretinopathy associated with adrenal myelolipoma. Klin Monatsbl Augenheilkd 2003;220:199-203.
20. Zamir E, Chowers I. Central serous chorioretinopathy in a patient with cryoglobulinaemia. Eye 1999;13:265-6.
21. Cunningham ET Jr, Alfred PR, Irvine AR. Central serous chorioretinopathy in patients with systemic lupus erythematosus. Ophthalmology 1996;103:2081-90.
22. Karashima K, Fujioka S, Harino S. Two cases of central serous chorioretinopathy treated with photocoagulation after bone marrow transplantation. Retina 2002;22:651-3.
23. Spahn C, Wiek J, Burger T, et al. Psychosomatic aspects in patients with central serous chorioretinopathy. Br J Ophthalmol 2003;87:704-8.
24. Kitaya N, Nagaoka T, Hikichi T, et al. Features of abnormal choroidal circulation in central serous chorioretinopathy. Br J Ophthalmol 2003;87:709-12.
25. Prunte C, Flammer J. Choroidal capillary and venous congestion in central serous chorioretinopathy. Am J Ophthalmol 1996;121:26-34.
26. Iijima H, Iida T, Murayama K, et al. Plasminogen activator inhibitor 1 in central serous chorioretinopathy. Am J Ophthalmol 1999;127:477-8.
27. Giusti C. Central serous chorioretinopathy: a new extragastric manifestation of Helicobacter pylori? Analysis of a clinical case. Clin Ter 2001;152:393-7.
28. Mauget-Faÿsse M, Kodjikian L, Quaranta M, et al. Rôle de l'Helicobacter pylori dans la choriorétinopathie séreuse centrale et l'épithéliopathie rétinienne diffuse. Résultats de la première étude prospective pilote. J Fr Ophthalmol 2002;25: 1021-5.
29. Franceschi F, Sepulveda AR, Gasbarrini A, et al. Cross-reactivity of anti-CagA antibodies with vascular wall antigens: possible pathogenic link between Helicobacter pylori infection and atherosclerosis. Circulation 2002;106:430-4.
30. Mayr M, Kiechl S, Mendall MA, et al. Increased risk of atherosclerosis is confined to CagA-positive Helicobacter pylori strains: prospective results from the Bruneck study. Stroke 2003;34:610-5.
31. Prasad A, Zhu J, Halcox JP, et al. Predisposition to atherosclerosis by infections: role of endothelial dysfunction. Circulation 2002;106:184-90.
32. Lamb DJ, El-Sankary W, Ferns GA. Molecular mimicry in atherosclerosis: a role for heat shock proteins in immunisation. Atherosclerosis 2003;167:177-85.
33. Georges JL, Rupprecht HJ, Blankenberg S, et al. Impact of pathogen burden in patients with coronary artery disease in relation to systemic inflammation and variation in genes encoding cytokines. Am J Cardiol 2003;92:515-21.
34. Byrne MF, Corcoran PA, Atherton JC, et al. Stimulation of adhesion molecule expression by Helicobacter pylori and increased neutrophil adhesion to human umbilical vein endothelial cells. FEBS Lett. 2002;532:411-4.
35. Byrne MF, Kerrigan SW, Corcoran PA, et al. Helicobacter pylori binds von Willebrand factor and interacts with GPIb to induce platelet aggregation. Gastroenterology 2003;124:1846-54.
36. Strowski MZ, Cramer T, Schafer G, et al. Helicobacter pylori stimulates host vascular endothelial growth factor-A (vegf-A) gene expression via MEK/ERK-dependent activation of Sp1 and Sp3. FASEB J. 2004;18:218-20.
37. Khairy P, Rinfret S, Tardif JC, et al. Absence of association between infectious agents and endothelial function in healthy young men. Circulation 2003;107:1966-71.
38. Neureiter D, Heuschmann P, Stintzing S, et al. Detection of Chlamydia pneumoniae but not of Helicobacter pylori in symptomatic atherosclerotic carotids associated with enhanced serum antibodies, inflammation and apoptosis rate. Atherosclerosis 2003;168:153-62.